Long-term follow-up of bladder cancer patients with disseminated tumour cells in bone marrow

Eur Urol. 2011 Aug;60(2):231-8. doi: 10.1016/j.eururo.2010.12.014. Epub 2010 Dec 22.

Abstract

Background: The clinical relevance of polymerase chain reaction (PCR)-based techniques for detection of disseminated tumour cells (DTCs) in the bone marrow of bladder cancer (BCa) patients is still under debate, as data on long-term follow-up analysis have not yet been published.

Objective: The aim of the present prospective study was to assess the prognostic significance of DTCs detected by cytokeratin-20 (CK20) reverse-transcriptase PCR in bone marrow from BCa patients undergoing radical cystectomy (RC).

Design, setting, and participants: Bone marrow samples from 51 BCa patients with high-risk non-muscle-invasive or muscle-invasive urothelial carcinoma were drawn from the anterior iliac crest prior to RC. CK20-positive cells in bone marrow were detected by qualitative RT-PCR.

Measurements: BCa patients with CK20 status were analysed with respect to the end points tumour progression and cancer death. A multivariate Cox regression analysis was performed to determine independent prognostic factors for progression-free survival (PFS), tumour-specific survival (TSS), and overall survival (OS).

Results and limitations: CK20-positive cells were detected in 16 of 51 (31.4%) BCa patients of all stages. BCa patients with CK20-negative status displayed a 7-yr PFS rate of 64% versus 35.2% for CK20-positive patients (p=0.007). TSS was significantly shorter in the CK20-positive group, with a 7-yr survival rate of 46.9% compared to CK20-negative patients with 70.2% (p=0.012). The 7-yr OS rate of 37.5% for CK20-positive patients was significantly <65.7% in the CK20-negative group (p=0.006). A subgroup analysis of lymph node-negative patients (pN0) discriminated by CK20 status revealed significant differences in PFS, TSS, and OS. In a multivariate analysis, CK20-status provides independent prognostic information with respect to all three survival end points.

Conclusions: BCa patients with positive CK20 status in bone marrow represent a high-risk subgroup reflected by an unfavourable outcome in the long-term analysis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Bone Marrow Examination
  • Bone Marrow Neoplasms / genetics
  • Bone Marrow Neoplasms / mortality
  • Bone Marrow Neoplasms / secondary*
  • Carcinoma / genetics
  • Carcinoma / mortality
  • Carcinoma / secondary*
  • Carcinoma / therapy
  • Chemotherapy, Adjuvant
  • Cystectomy
  • DNA, Neoplasm / analysis*
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Germany
  • Humans
  • Kaplan-Meier Estimate
  • Keratin-20 / genetics
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Prognosis
  • Proportional Hazards Models
  • Prospective Studies
  • Reverse Transcriptase Polymerase Chain Reaction
  • Risk Assessment
  • Risk Factors
  • Survival Rate
  • Time Factors
  • Urinary Bladder Neoplasms / genetics
  • Urinary Bladder Neoplasms / mortality
  • Urinary Bladder Neoplasms / pathology*
  • Urinary Bladder Neoplasms / therapy

Substances

  • DNA, Neoplasm
  • KRT20 protein, human
  • Keratin-20